Bausch Health Companies Inc.
No SEC Form 4 filings for $BHC in the last 30 days.
Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results and an improved 2026 outlook, according to the article. Q2 non-GAAP EPS was $1.26 vs $1.01 consensus, revenue $2.85B vs $2.66B. The company reported free cash flow around $593M and lifted 2026 guidance to revenue $10.79B-$11.04B and adjusted EBITDA $4.05B-$4.175B.
Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results beat expectations and 2026 guidance was raised, according to the article. Q2 revenue was about $2.85B vs $2.66B expected, non-GAAP EPS $1.26 vs $1.01, with $670M operating cash flow and $593M free cash flow. The stock moved from the $4s to near $6.9.
Bausch Health Companies Inc. (BHC) shares rose about 13.6% after the company reported Q2 results and raised 2026 guidance, according to the article. Q2 revenue was $2.85B and non-GAAP EPS $1.26. 2026 outlook calls for revenue of $10.79B to $11.04B and adjusted EBITDA of $4.05B to $4.175B.
Over the past 7 days, alphai's AI scored 3 news stories mentioning BHC (Bausch Health Companies Inc.). Coverage has skewed bullish: 3 bullish, 0 neutral, and 0 bearish.
Recent BHC coverage spans earnings and market movers.
The text frames a post-earnings rerating driven by stronger cash generation, improving debt/restructuring prospects, and higher 2026 revenue and adjusted EBITDA guidance.
Earnings beat plus raised guidance and cash flow strength likely drive near-term momentum, but leverage and litigation headline risk can cap follow-through.
The disclosed beat and raised 2026 outlook are the immediate catalyst behind the reported sharp repricing, with liquidity and leverage still key swing factors.
Guidance upgrades and profitability improvement are likely to sustain upward momentum, but the magnitude of the move raises near-term volatility risk.
Guidance lift plus stronger Q2 fundamentals is a direct earnings-and-outlook catalyst for re-pricing the stock.
alphai scores every news story that mentions BHC with an AI model for sentiment and relevance, and aggregates insider trades from Bausch Health Companies Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Bausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results and an improved 2026 outlook, according to the article. Q2 non-GAAP EPS was $1.26 vs $1.01 consensus, revenue $2.85B vs $2.66B. The company reported free cash flow around $593M and lifted 2026 guidance to revenue $10.79B-$11.04B and adjusted EBITDA $4.05B-$4.175B.
6 min readBausch Health Companies Inc. (BHC) shares rose about 13.6% after Q2 results beat expectations and 2026 guidance was raised, according to the article. Q2 revenue was about $2.85B vs $2.66B expected, non-GAAP EPS $1.26 vs $1.01, with $670M operating cash flow and $593M free cash flow. The stock moved from the $4s to near $6.9.
6 min readBausch Health Companies Inc. (BHC) shares rose about 13.6% after the company reported Q2 results and raised 2026 guidance, according to the article. Q2 revenue was $2.85B and non-GAAP EPS $1.26. 2026 outlook calls for revenue of $10.79B to $11.04B and adjusted EBITDA of $4.05B to $4.175B.
6 min readBausch Health (NYSE:BHC) climbed by 28.85 percent on Thursday to end at $6.03 apiece, after announcing a strong second quarter of the year that set the ground for the company’s profit recovery. In an updated report, the pharmaceutical giant said that it swung to a net income of $260 million during the period, marking a 103 percent jump from the $128 million in the same period last year, and helping slash its net loss to $1.171 billion from the $1.431 billion in the previous quarter of the year.
4 min readToday's top gainers included Glucotrack, whose subsidiary announced progress in the development strategy for LT-100, a novel non-narcotic therapy; Nuwellis, following expanded clinical recognition for its Aquadex therapy; Bausch Health, after reporting strong second-quarter 2026 results and raising its outlook; and Corcept Therapeutics, after posting robust second-quarter 2026 results, among others. Read on… GCTK's LT-100 Program Moves Forward Glucotrack Inc.
6 min readBanks, Bausch Rate Attention Equities in Canada’s largest market jumped Thursday, as oil prices retreated once again, and as health-care issues competed with resource stocks as top gainers. The TSX forged ahead 172.06 points to end Thursday at 35,505.84. The Canadian dollar added 0.17 cents at 71.41 cents U.S. Vermilion Energy and Kinross Gold posted higher second-quarter profits amid a flurry of earnings releases from energy and mining companies late Wednesday.
4 min readLightspeed, Thomson in Spotlight Canada's main stock index edged lower in choppy trading on Thursday, as gains in mining and heavyweight financial stocks were countered by losses in technology and industrials shares. The TSX headed south 37.04 points to reach noon EDT Thursday at 35,296.74. The Canadian dollar added 0.13 at 71.38 cents U.S. Vermilion Energy and Kinross Gold posted higher second-quarter profits amid a flurry of earnings releases from energy and mining companies late Wednesday.
6 min readBausch Health Companies (BHC) reported record Q2 revenue and higher adjusted EBITDA, with all segments contributing and strong cash flow used to reduce debt. The company raised full-year guidance across key metrics, but expects H2 growth to slow due to inventory, generic competition, and Medicaid/340B headwinds.
1 min readBausch Health (NYSE:BHC) reported Q2 2026 results on July 29, with adjusted EPS of $1.26 and revenue of $2.85B, beating forecasts. The company said adjusted EBITDA rose 28% to $1.08B and raised full-year 2026 guidance for Bausch excluding B+L. Shares rose to $4.68, up 3.65% in regular trading.
6 min readBausch Health reported Q2 2026 adjusted earnings of $1.26 per share on revenue of $2.85B, beating forecasts of $1.03 and $2.66B, respectively, according to the company. It raised full-year 2026 guidance for revenue, adjusted EBITDA and operating cash flow. Shares rose 3.65% and 3.21% after hours to $4.83.
6 min read
